Sudan Journal of Medical Sciences (SJMS) | Sudan JMS: Volume 12 (2017), Issue No. 4 | pages: 215-230

DOI: 10.18502/sjms.v12i4.1353

Association between Exposure to Beta 2 Agonists and Corticosteroids and Acquiring Benign Joint Hypermobility Syndrome among Asthmatic Patients: a Case-Control Study

Alsarah Mutwakil Abbas Diab

Eman MutwakilAhmedAlmostafa Suliman

AyatAbdallah Hassan Abdallah

Mohamed AbdelhadiElzubair Dyab

Tanzeel Omer Elamin Awadalla

Naila Mubarak Kirkisawi

Nazik Elmalaika Obaid Seid Ahmed Husain


Background:Beta2 (β2) agonists as relievers and corticosteroids as controllers are the mainstay drugs for asthma treatment. Benign Joint Hypermobility Syndrome (BJHS) is a connective tissue disorder with musculoskeletal symptoms.

We had examined the possible association between the use of β2 agonists and corticosteroids and acquiring BJHS in asthmatic patients.

Methods:This was a case-control, hospital-based study including a group of asthmatics who had BJHS (cases), compared with a matched group of asthmatics without BJHS (controls) for the β2 agonists and corticosteroids past and current pattern of use. Information was collected by face-to-face interview and clinical examination and from subjects’ medical records using pre-structured questionnaire. BJHS diagnosis was based on the revised Brighton criteria. Asthma severity was reflected by a score, which was calculated from the asthma questionnaire. Comparison of exposure was done by Calculation of Odds Ratio.


Development of BJHS was found to be significantly associated with chronicity of asthma of average duration of 13.2 years, and hence to prolonged use of β2 agonists and/or corticosteroids (OR 1.019; 95% CI 0.999 - 1.039, P=0.006)

Exposure to β2 agonist and corticosteroid (87 and 79 cases and controls respectively P=0.05)high asthma score (42.9 ± 9.8 and 40.4 ± 8.3 among cases and controls respectively, P=0.011) were significantly associated with the development of BJHS.


  • Downloads 0
  • Views 703

Article Tools



ISSN: 1858-5051